myRAteam

JAK inhibitors, such as Tofacitinib (Xeljanz®), Baricitinib (Olumiant®), and Upadacitinib (Rinvoq®), are prescribed for rheumatoid arthritis, especially if methotrexate is not tolerated or effective.

Effectiveness
- Improvement in symptoms can be seen in as little as two weeks.
- Full effectiveness typically takes three Show Full Answer

JAK inhibitors, such as Tofacitinib (Xeljanz®), Baricitinib (Olumiant®), and Upadacitinib (Rinvoq®), are prescribed for rheumatoid arthritis, especially if methotrexate is not tolerated or effective.

Effectiveness:
- Improvement in symptoms can be seen in as little as two weeks.
- Full effectiveness typically takes three to six months.

Side Effects:
- Common: Nausea, indigestion, diarrhea, headaches, upper respiratory tract infection, increased cholesterol levels.
- Rare but serious: Infection, abnormal blood counts, abnormal liver function tests, increased risk of bowel perforation, decreased kidney function.

FDA Warnings:
- Higher rates of heart events, certain cancers, and blood clots.
- Recommended to try TNF inhibitors before JAK inhibitors.

Always consult your doctor for personalized advice.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Janus Kinase (JAK) Inhibitors – CreakyJoints

JAK Inhibitors and FDA Warnings: What Arthritis Patients Need to Know